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Hemophilia A is caused by a genetic mutation in coagulation factor VIII (FVIII) gene and gene therapy is considered to be a 
promising strategy for its treatment. We recently demonstrated that co-delivery of two vectors expressing M662C mutated 
heavy and D1828C mutated light chain genes of B-domain-deleted coagulation factor VIII (BDD-FVIII) leads to inter-chain 
disulfide cross-linking and improved heavy chain secretion in vitro. In this study, co-injection of both M662C and D1828C 
mutated BDD-FVIII gene expression vectors into mice resulted in increased heavy chain secretion and coagulation activity in 
plasma in vivo. Approximately (239±56) ng mL1 above endogenous levels of transgenic FVIII heavy chain was found in 
mouse plasma using a chain-specific ELISA. For FVIII coagulation activity, approximately (1.09±0.25) IU mL1 above en-
dogenous levels were detected in co-injected transgenic mouse plasma using a chromogenic assay. These data demonstrate that 
inter-chain disulfide bonds likely increase heavy chain secretion and coagulation activity in the plasma of transgenic mice with 
an improved efficacy of a dual-vector delivery of BDD-FVIII gene. These findings support our ongoing efforts to develop a 
gene therapy for hemophilia A treatment using dual-AAV vectors. 
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The current treatment for hemophilia A is protein replace-
ment by using plasma concentrates and recombinant coagu-
lation factor VIII (FVIII), but this approach is limited be-
cause of the high cost and other drawbacks such as the risk 
of transmission of blood-borne infectious diseases. Since 
hemophilia A is a disease caused by a single gene deficien-
cy, gene therapy is considered to be a particularly suitable 
and promising treatment [1]. Adeno-associated virus (AAV) 
vectors are ideal gene delivery vehicles for the stable ex-
pression of transgenes, and their non-pathogenic, replica-
tion-defective characteristics, but proved difficult for the 
transfer of the FVIII gene because of their capacity con-
straint [2]. The separate delivery of FVIII heavy chain (HC) 
and light chain (LC) genes by a dual-vector is one strategy 
to circumvent the packaging limit of AAV vectors, but 
transgenic efficacy is adversely affected because of the in-
efficient secretion of the HC [3,4]. In addition, it was pre-
viously demonstrated that von Willebrand factor (vWF) is 
needed for the assembly of HC and LC to form the stable 
functional FVIII heterodimer, and helpful for its secretion in 
Chinese hamster ovary cells [5]. 
We previously reported that the FVIII LC promotes HC 
secretion in cis, and HC L303E/F309S mutations reduce its 
affinity to the endoplasmic reticulum (ER) protein molecu-
lar chaperone, BiP. This in turn enhances the release of 
spliced FVIII protein and secretion using protein trans-   
splicing technology based dual vectors to transfer the FVIII 
gene [6]. Studies performed by Gale et al. [7] have shown 
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that the M662C mutation in the HC and the D1828C muta-
tion in the LC can form a disulfide bond, and upon activa-
tion by thrombin hydrolysis, the activity of the active FVIII 
(FVIIIa) product was unchanged with a prolonged half-life 
and improved affinity for vWF. Our recent work using a 
dual vector system to transduce cultured cells with a 
M662C/D1828C mutant B-domain-deleted FVIII (BDD-     
FVIII) gene showed an inter-chain disulfide cross-linking 
between intracellularlly co-expressed HC and LC that sig-
nificantly improved HC secretion [8]. In this study, a dual 
vector strategy was used to deliver a M662C/D1828C mu-
tant BDD-FVIII gene into mice and observed increased 
plasma levels of HC secretion and coagulation activity. 
These studies provide an experimental basis for the ongoing 
study of hemophilia A gene therapy.  
1  Materials and methods 
1.1  Materials 
Human BDD-FVIII expression vector, pCMV-F8, and indi-
vidual Ssp DnaB intein-fused HC and LC expression vec-
tors, pCMV-HCIntN and pCMV-IntCLC, respectively, 
were constructed and described in our previous study [9]. 
C57BL/6 mice were obtained from Vital River Laborato-
ries (VRL, Beijing, China).  
High fidelity DNA polymerase Pfu was purchased from 
Stratagene (Santa Clara, CA, USA). The DNA ligase kit 
was purchased from New England Biolabs (Ipswich, MA, 
USA). The Gel Extraction kit, PCR purification kit, Spin 
Miniprep kit, and HiSpeed Plasmid Midi Kit were obtained 
from Qiagen (Dusseldorf, Germany). Recombinant human 
reference factor VIII was purchased from BioChain (Hay-
ward, CA, USA). The FVIII HC-specific monoclonal anti-
body (ESH5) and LC-specific monoclonal antibody (ESH8) 
were obtained from American Diagnostica (Greenwich, CT, 
USA). The horseradish peroxidase (HRP)-conjugated rabbit 
anti-human FVIII polyclonal antibody was purchased from 
Novus (Littleton, CO, USA). Normal pooled human refer-
ence plasma and FVIII-deficient plasma were obtained from 
George King Biomedical (Overland Park, KA, USA). The 
COATEST SP FVIII functional analysis kit was purchased 
from Chromogenix (Milan, Italy). 
1.2  Vector construction 
To delete the intein coding sequences fused to BDD-FVIII 
HC and LC in plasmids pCMV-HCIntN and pCMV-IntCLC, 
a Pfu Turbo DNA polymerase catalyzed inverse polymerase 
chain reaction (PCR) was performed with primers 5′- 
CCGTTTAAACCCGCTGATCAG-3′ (forward) and 5′-CT- 
GAAGAGTAGTACGAGTTA TTTC-3′ (reverse) using 
pCMV-HCIntN as a template, and primers 5′-TCAGATC- 
AAGAGGAAATTGACTATG-3′ (forward) and 5′-ACTA-  
AAGCAGAATCGCAAAA GGC-3′ (reverse) using CMV- 
IntCLC as a template. Both linear PCR products were 
self-ligated respectively to obtain the HC expression vector, 
pCMV-HC, and the LC expression vector, pCMV-LC. Both 
plasmids were then used as templates for inverse PCR to 
introduce M662C point mutation in pCMV-HC using 5′-    
TGTGTCTATGAAGACACACTCACC-3′ (forward) and 
5′-TTTGTGTTTGAAGGTATATCCAG-3′ (reverse), and 
D1828C point mutation in pCMV-LC with primer pairs 5′- 
TGTGAGTTTGACTGCAAAGCCTG-3′ (forward) and 5′- 
TTTAGTGGGTGCCATATGATG-3′ (reverse). PCR prod-
ucts were self-ligated to yield the circular M662C mutated 
HC expression vector, pCMV-C662HC, and D1828C mu-
tated LC expression vector, pCMV-C1828LC.  
1.3  Animal experiments 
C57BL/6 mice were injected with 200 g of column-puri-     
fied pCMV-C662HC and pCMV-C1828LC plasmids in 2 mL 
saline via the portal vein, as described by Burton et al. [3]. At 
48 h after injection of vectors, blood samples were collected 
by tail clipping in an anticoagulant at a final concentration 
of 0.38% (w/v) sodium citrate. Blood samples were centri-
fuged at 2000×g for 10 min at 4°C in a microcentrifuge and 
plasma was collected and analyzed for HC and LC antigen 
and coagulation activity. 
1.4  Quantitative analysis of FVIII antigen in plasma 
Chain-specific enzyme-linked immunosorbent assays 
(ELISAs) were performed to determine BDD-FVIII HC and 
LC concentration in plasma, as previously described [10]. 
Human recombinant FVIII protein was used as a standard 
and diluted in plasma blocking buffer in the range of 
10–320 ng mL1. For ELISA, 96-well plates were coated 
with 2 g mL1 human FVIII HC-specific monoclonal anti-
body, ESH5, or LC-specific monoclonal antibody, ESH8, 
overnight at 4°C followed by washing and then blocked 
with blocking buffer for 2 h at 37°C. Plates were washed 
and diluted standard or plasma samples were applied and 
incubated at 37°C for 1 h. After washing, HRP-conjugated 
FVIII polyclonal antibody was added for continuing incuba-
tion for 1 h at 37°C. Plates were washed and the o-phen-      
ylenediamine dihydrochloride (OPD) substrate was added 
and incubated for 30 min at 37°C. The reaction was stopped 
by the addition of 2 mol L1 H2SO4 and the plates were read 
at a wavelength of 490 nm. A standard curve was plotted 
according to the absorbance value versus concentration of 
the diluted standards, and transgenic human HC and LC 
concentrations in plasma samples were deduced from the 
standard curve.  
1.5  Analysis of FVIII coagulation activity  
A Coatest chromogenic assay was used to detect 
transgene-produced human FVIII coagulation activity in 
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mouse plasma, as described by Burton et al. [3], with some 
modifications. Total FVIII activity detected in transgenic 
mouse plasma comprised both mouse and human-derived 
activity. Normal pooled human plasma was used as a stand-
ard and one unit activity was defined as 200 ng FVIII in 1 
mL of this plasma. The standard was serially diluted in 
FVIII-deficient human plasma ranging from 1 (undiluted) to 
0.0313 U mL1. For the assays, 10 L of each diluted 
standard was incubated at 37°C for 15 min with or without 
2 L ESH8 antibody (1 mg mL1). Similarly, 10 L of di-
luted mice plasma samples in FVIII-deficient plasma was 
incubated at 37°C for 15 min without ESH8, or with 2 L 
ESH8 to deplete human FVIII activity. Standards with and 
without treatment were prepared according to the manufac-
turer’s instructions and read at 405 nm. A standard curve 
was plotted according to the difference in absorbance be-
tween untreated and ESH8-treated standards versus corre-
sponding FVIII activity. The absorbance values of plasma 
samples were also measured at 405 nm and FVIII activity 
was extrapolated using the standard curve. The difference of 
FVIII activity between the ESH8-untreated sample and 
ESH8-treated sample represented the human FVIII activity 
produced by the transgene.  
1.6  Statistical analysis 
Data are expressed as mean±standard deviations and statis-
tical comparisons were based on student’s t-test. A P-value 
of <0.05 was considered significant. 
2  Results 
2.1  Construction of BDD-FVIII heavy and light chain 
mutants 
FVIII has a domain structure order from N- to C-terminus 
arranged as A1-A2-B-A3-C1-C2 and BDD-FVIII was pro-
duced by deleting most of the nucleotides in the B domain 
from the I761 codon to the N1639 codon. By truncating 
BDD-FVIII before codon S1657, the resulting HC and LC 
coding sequences were independently inserted into plasmid 
vector pcDNA3.1(+) to derive expression vectors for HC 
and LC, pCMV-HC and pCMV-LC. A Cys mutation of 
M662 in HC and D1828 in LC was made using PCR-medi-     
ated site-directed mutagenesis using pCMV-HC and 
pCMV-LC as templates to produce Cys-mutated HC and LC 
expression vectors, pCMV-C662HC and pCMV-C1828LC, 
respectively. All constructs are showed in Figure 1.  
2.2  Plasma HC secretion in mice administered dual- 
vector BDD-FVIII 
To examine whether inter-chain disulfide linking facilitated 
plasma HC secretion in mice, a chain-specific ELISA was 
used to measure the amount of human BDD-FVIII HC in 
plasma and was determined to be (239±56) ng mL1, much 
higher in comparison to the wild-type human HC secretion 
in control mice ((84±25) ng mL1) (Figure 2). In the plasma 
of pCMV-C662HC or pCMV-HC alone injected mice, both 
showed extremely low HC secretion ((18±9) and (12±7) ng 
mL1, respectively). The plasma secretion of HC in mice 
injected with the BDD-FVIII transgene was shown to be 
(416±52) ng mL1. These data demonstrated that wild-type 
HC is inefficiently secreted, but in the presence of LC, HC 
secretion is significantly increased regardless of disulfide 
bond formation, indicating that LC could improve HC se-
cretion both in cis and trans. 
As shown in Figure 3, the secretion of LC in plasma was 
determined by chain-specific ELISA and showed similar 
plasma levels for mice co-injected with pCMV-C662HC 
and pCMV-C1828LC or injected with pCMV-C1828LC 
alone ((809±72) vs. (875±107) ng mL1). Mice co-injected 
with pCMV-HC and pCMV-LC or injected with pCMV-LC 
also displayed similar LC secretion ((779±125) vs. (835± 
 
 
Figure 1  Schematic representation of factor VIII and its derivatives. The FVIII has a domain organization of A1-A2-B-A3-C1-C2. BDD-F VIII is derived 
from FVIII by deleting the B-domain from Ile761 to Asn1639. HC and LC represent the heavy and light chains by cutting BDD-FVIII before Ser1657. 
C662HC and C1828LC are Cys mutants of HC at M662 and LC at D1828, respectively. SS, signal sequence of FVIII. 
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Figure 2  Inter-chain disulfide cross-linking enhances plasma secretion of 
heavy chain. *, P>0.05; **, P<0.01. 
 
Figure 3  Inter-chain disulfide cross-linking has no effect on plasma 
secretion of light chain. *, P>0.05. 
 
Figure 4  Inter-chain disulfide cross-linking improves plasma bioactivity. 
**, P<0.01. 
139) ng mL1). These findings suggested that LC secretion 
is highly efficient compared with HC. The amount of LC 
secreted in mice receiving the BDD-FVIII gene is tightly 
related to HC because both chains have a 1:1 stoichiometric 
relationship in secreted BDD-FVIII. The ratio of HC to LC 
in the plasma of mice co-injected with Cys-mutated HC and 
LC that is capable of forming inter-chain disulfide bonds 
was 1:3.4 but the ratio was 1:9.3 in plasma without engi-
neered inter-chain disulfide bonds, indicating that the inter-     
chain disulfide bonds could partially relieve the chain im-
balance by promoting HC secretion. 
2.3  Inter-chain bonding increases plasma coagulation 
activity 
Plasma collected from mice injected with the dual-vector 
were analyzed for FVIII coagulation activity using Coatest 
method. Coagulation activity found in plasma from mice 
co-administered Cys-mutated HC and LC genes ((1.09±0.25) 
IU mL1) was considerably higher than for control mice 
((0.36±0.12) IU mL1) but less than for those that received 
the BDD-FVIII gene ((2.01±0.63) IU mL1). This demon-
strated that mutated Cys residues in HC and LC can im-
prove plasma coagulation activity in mice administered the 
dual-vector through inter-chain disulfide bonding. Assum-
ing that 100% of HC secreted in the plasma from BDD-      
FVIII gene injected mice was functionally active, mice re-
ceiving Cys mutated HC and LC vectors separately had 
91% of HC contributed to coagulation activity, while being 
85% in control mice. These findings suggest that inter-chain 
disulfide bonds improve the assembly of functional hetero-
dimer BDD-FVIII from separately expressed HC and LC 
proteins. 
3  Discussion 
Previous studies have demonstrated the ability of AAV 
vectors to express sustained levels of coagulation factor IX 
either by liver- or skeletal muscle-targeted gene delivery 
approaches [11,12]. Thus, AAV vectors provide a promis-
ing gene delivering system for the treatment of hemophilia 
A by gene therapy. However, the major obstacle for the use 
of AAV vectors for hemophilia A gene therapy lies with the 
large FVIII gene that exceeds the packaging capacity. It has 
been revealed that the majority of the FVIII protein ex-
pressed from FVIII gene transfected cells is hydrolyzed to 
heavy and light chains in the Golgi apparatus during 
post-translational processing and then secreted as a func-
tional FVIII heterodimer [13]. Based on this understanding, 
a dual-vector strategy for FVIII gene split transfer was de-
veloped for the study of hemophilia A gene therapy [3,4].  
Although FVIII and another coagulation factor, factor  
V (FV), share 40% sequence homology in the A and C do-
mains, the full-length FVIII protein shows less efficient 
secretion than FV [14]. The molecular mechanism respon-
sible for FVIII inefficient secretion, is mainly caused by the 
association of the A1 domain in the HC with several protein 
chaperones, including the immunoglobin-binding protein 
(BiP) in the lumen of the endoplasmic reticulum (ER) dur-
ing intracellular processing, and thus the release of FVIII 
from BiP is dependent on a high concentration of intracel-
lular ATP [15]. In addition, N-linked oligosaccharides in 
the B-domain of the FVIII heavy chain can also facilitate 
FVIII secretion by participating in the folding interactions 
within the ER as well as potentially helping facilitate 
ER-Golgi transport [16]. Our previous work has shown that 
dual-vector BDD-FVIII gene transfected cells have similar 
expression levels of intracellular HC and LC [10]. There-
fore, dual-vector mediated FVIII gene transfer can over-
come the capacity constraints of AAV vectors, but the inef-
ficient secretion of the HC leads to its excessive intracellu-
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lar deposition, which not only reduces the efficacy of gene 
therapy, but may also destabilize host cells and possibly 
induce apoptosis [17]. Moreover, the excessively secreted 
non-functional LC may also cause host immune responses. 
With introduction of Cys mutations in both heavy and 
light chains that are capable of forming inter-chain disulfide 
bonds, the secretion of the FVIII HC was significantly im-
proved by a dual-vector containing the BDD-FVIII gene in 
transfected cells [8]. Using an in vivo dual-vector mediated 
liver-targeting gene delivery in mice, the present study 
showed that Cys mutations promoted the formation of an 
inter-chain covalent disulfide bond between HC and LC, 
and improved the secretion of the HC in mouse plasma. In 
this case, increased HC secretion levels lead to the antigen 
ratio of HC to LC being approximately 1:3.4, while this 
ratio was 1:9.3 in the plasma of wild type BDD-FVIII gene 
dual-vector injected mice showing an obvious lower HC 
secretion. It suggested that the chain imbalance could be 
partially relieved in the presence of Cys mutations. With the 
increase in the amount of HC secretion, BDD-FVIII hetero-
dimer was formed more efficiently from matched HC and 
LC, which not only improves the clotting activity of the 
plasma, but also reduces the amount of non-functional light 
chain. Meanwhile, decreased cellular deposition of heavy 
chain may help reduce cellular stress response in transduced 
cells.  
The analysis of LC secretion in the plasma revealed that 
the LC was highly secreted and not affected in LC gene 
administered alone, co-administered with the HC gene, or in 
the presence of inter-chain disulfide. However, the secretion 
of the HC was inefficient but improved significantly when 
LC was present, much higher especially when inter-chain 
disulfide bond formed. Studies by Chen et al. [18] have 
shown that the secretion of LC facilitates HC secretion 
through its N-terminal acidic region 3 (ar3), where a mutant 
HC with an additional ar3 sequences at the C-terminus ex-
hibits three- to five-fold higher secretion in vitro. In addi-
tion, ar3 has a role in mediating interaction of FVIII with 
vWF [19], but unlikely to be related to this function. When 
an inter-chain disulfide bond is formed, the secretion of HC 
increased likely driven by covalently bonded LC. In our 
recent studies using protein trans-splicing mediated du-
al-vector FVIII gene co-transfection in cultured cells, a 
cis-promoting effect of LC covalently linked to the HC by 
peptide bond on the HC secretion was found [6,10]. 
The secreted levels of heterodimer FVIII determines 
plasma clotting activity. Although in vitro studies have 
shown that a heterodimer FVIII can be formed from isolated 
heavy and light chains at high concentrations and in the 
presence of Mn2+ or Ca2+ ions [20], the heterodimerization 
of separately expressed heavy and light chains may only 
occur intracellularly. In addition, vWF can act to promote 
the stable assembly of FVIII subunits at the site of secretion, 
but physiological vWF is mainly produced in vascular en-
dothelial cells and megakaryocyte cells, but not in hepato-
cytes [21]. As functional heterodimeric FVIII is produced 
only from cells with coexpressed HC and LC, therefore, the 
efficacy of the dual-vector strategy depends on the effi-
ciency of the co-transfection of both vectors. The proportion 
of active HC in total plasma HC may reflect the efficiency 
of forming functional heterodimer in dual-vector strategy. 
In comparison to 85% of plasma HC being functionally 
active in the absence of inter-chain disulfide bonds, 91% 
HC was contributed to the functional heterodimer generat-
ing a higher plasma clotting activity in the presence of di-
sulfide. These findings are consistent with an observation 
by Gale et al. [7] that also showed that Cys mutation does 
not affect the activity of the heterodimer. Recently, Sabatino 
et al. [22] reported that the amount of FVIII activity in 
plasma of dual-vector administered hemophilia A dog mod-
el correlated closely with the amount of HC in the plasma, 
suggesting a higher co-transfection efficiency. 
In summary, we have demonstrated the feasibility of the 
introduction of Cys mutations that promote inter-chain di-
sulfide cross-linking for improving the dual-vector strategy 
of FVIII gene delivery. This approach was proven to facili-
tate the assembly of the heavy and light chains into func-
tional heterodimeric FVIII leading to an enhancing secre-
tion of plasma HC and coagulation activity in vivo. The 
present study provides an experimental basis for ongoing 
investigation of the use of dual-AAV vectors for the treat-
ment of hemophilia A in animal models.  
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